China (Mainland)
Diamondsupplier 
Anticancer API Letrozole CAS NO.112809-51-5
- Min.Order: 1 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Product Details
Keywords
- Letrozole powder CAS:112809-51-5
- High quality Letrozole API powder
- Letrozole CAS:112809-51-5
Quick Details
- ProName: Anticancer API Letrozole
- CasNo: 112809-51-5
- Molecular Formula: C17H11N5
- Appearance: White to yellowish, crystalline powder
- Application: It is suitable for the treatment of p...
- DeliveryTime: within 7-10 days after order
- PackAge: 25kg/drum or per customer's requiremen...
- Port: Beijing/Shanghai/Hangzhou/Shenzhen
- ProductionCapacity: 1000 Kilogram/Month
- Purity: 98.0% to 102.0%
- LimitNum: 1 Kilogram
- Related Substances: Any other impurity: Not more than 0.1%
- Residue on Ignition: Not more than 0.1%
- Heavy Metal: Not more than 0.001%
- Valid Period: 2 years
- Water: Not more than 0.3%
Superiority
1) Specialized in pharmaceutical industry since from 1987
2) ISO 9001:2015 & SGS audited supplier
3) Accept better payment terms : T.T 30-60 days.on the basic of pass SINOSURE credit investigation.
5) We have warehouse in USA with quickly shipment .
6) We can do different terms of FOB ,CIF/CIP ,DDP ...
Details
|
Product Information |
|
Product name |
Letrozole |
|
Molecular Formula |
C17H11N5 |
|
Molecular Weight |
285.3 |
|
CAS No. |
112809-51-5 |
|
Quality Standard |
USP32, medical grade |
|
Appearance |
White powder |
|
COA of Letrozole |
|
Items |
Specification |
|
Appearance |
White to yellowish, crystalline powder |
|
Identification |
A.IR spectrum of sample should be identical to that of Reference Standard; |
|
The retention time of major peak in the chromatogram of the Assay preparation should correspond to that in the chromatogram of Standard preparation, as obtained in the Assay. |
|
|
Showing the white precipitate reaction. |
|
|
Water |
Not more than 0.3% |
|
Residue on Ignition |
Not more than 0.1% |
|
Heavy Metals |
Not more than 0.001% |
|
Related Compounds |
Compound A: Not more than 0.1% |
|
4,4’,4”-methylidenetrisbenzonitrile: Not more than 0.2% |
|
|
Any other impurity: Not more than 0.1% |
|
|
All other impurities: Not more than 0.3% |
|
|
Residual Sovents |
Ethanol: Not more than 3000ppm |
|
Ethyl acetate: Not more than 2000ppm |
|
|
DMF: Not more than 880ppm |
|
|
Microbe Limit |
Bacteria: Not more than 200/g |
|
Mold and yeast: Not more than 50/g |
|
|
Escherichia coli: should be absent |
|
|
Assay(anhydrous) |
98.0% to 102.0% of Cl7H11N5 on dried basis |
|
Packaging and Storage |
Preserve in tight containers at controlled room temperature. |
|
Conclusion |
Conforms to the USP32. |
|
Usage |
Letrozole is a new generation of highly selective aromatase inhibitors. It is a synthetic benztriazole derivative. By inhibiting aromatase, estrogen levels are reduced, thereby eliminating the stimulating effect of estrogen on tumor growth. The activity in the body is 150-250 times stronger than that of the first generation aromatase inhibitor amuromet. Because of its high selectivity, it does not affect glucocorticoids, mineralocorticoids, and thyroid function. Large doses have no inhibitory effect on the secretion of adrenal corticosteroids, so it has a high therapeutic index. Various preclinical studies have shown that letrozole has no potential toxicity, mutagenicity and carcinogenic effects on various systems and target organs in the whole body, and has less toxic and side effects, and is well tolerated. Compared with estrogen drugs, the anti-tumor effect is stronger. It is suitable for the treatment of postmenopausal patients with advanced breast cancer who are not responding to anti-estrogen therapy and early treatment of breast cancer.
In December 2005, the British drug and health product regulatory agency approved Letrozole (Fron) produced by Novartis of Switzerland to be used in the treatment of breast cancer patients, allowing it to be used in surgically treated, early menopausal hormone-positive mammary glands Cancer patients. This is the second aromatase inhibitor approved following the approval of AstraZeneca ’s Rainin in June 2005. Both drugs have shown in clinical trials that they can better prevent the risk of breast cancer recurrence compared to current standard tamoxifen treatment.
|
Company information |
Sinoway Industrial co., ltd. was established in 1987 in Xiamen, China, and now has been a leading group specialized in research, development, custom manufacturing and trading of pharmaceutical intermediates, APIs, health and food supplements, cosmetic raw materials, herbal extracts, polypeptides and prostaglandin derivatives, etc..
